Astrazeneca Drug Boost, UK Supermarkets, Travis Perkins Falls

On this episode of Stock Movers:

- AstraZeneca's experimental cholesterol drug significantly reduced “bad” cholesterol in a mid-stage trial, boosting hopes for a potential blockbuster that could be part of a powerful combination medicine targeting weight loss and related ailments. The once-a-day pill led to a 50.7% reduction in low-density lipoprotein cholesterol, often called LDL, when given on top of statins, according to data presented at the American College of Cardiology in Chicago.

- UK supermarket stocks decline as analysts cut profit estimates following a recent profit warning from Asda who are reducing prices on 10,000 items, likely signaling a period of more aggressive market activity after managing challenges from Aldi and Lidl. Tesco and Sainsbury's will have to respond to Asda, which is seeking to reestablish itself as the UK's cheapest full-line supermarket.

- Travis Perkins shares fall as much as 13% to their lowest since June 2009 after the wholesaler said there was uncertainty regarding recovery in UK construction activity and challenging market conditions have continued. Citi sees consensus downgrades on the back of the guidance.

See omnystudio.com/listener for privacy information.